| Identification | Back Directory | [Name]
NICOTINAMIDE HYDROCHLORIDE | [CAS]
25334-23-0 | [Synonyms]
NICA-001
nicotinamideHCl
Einecs 246-862-3
NIACINAMIDE HYDROCHLORIDE
NICOTINAMIDE HYDROCHLORIDE
OBLVPWTUALCMGD-UHFFFAOYSA-N | [EINECS(EC#)]
246-862-3 | [Molecular Formula]
C6H7ClN2O | [MDL Number]
MFCD00054325 | [MOL File]
25334-23-0.mol | [Molecular Weight]
158.59 |
| Hazard Information | Back Directory | [Uses]
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity[1][2][3][4]. | [in vivo]
Nicotinamide Hydrochloride (Intraperitoneal injection, 1500 and 1800 mg/Kg, 5 days per week) inhibits tumor growth in murine metastatic melanoma model[1].
Nicotinamide Hydrochloride (Intraperitoneal injection, 1800 mg/Kg, once a day, murine metastatic melanoma model) affects IFN-γ (a key mediator of cell-mediated anti-tumor immunity), increases the plasma levels of Eotaxin and IL-5, reduces the plasma levels of IL-3, IL-12, RANTES and IL-10[1].
Nicotinamide Hydrochloride (vein injection, 0-200 mg/kg, 5 days) inhibits HBV replication in HBV-transgenic mice[3]. | Animal Model: | C57BL/6 mice (subcutaneous injected with B16-F10 cells)[1] | | Dosage: | 1000, 1500, 1800 mg/Kg. | | Administration: | Intraperitoneal injection, 5 days per week (followed by 2-day rest) or once a day. | | Result: | Inhibited tumor growth at 1500 and 1800 mg/Kg, and had no effect on the body weight.
Increased the frequency of IFN-γ producing cells and modulated the protein levels of cytokines and chemokines in the plasma of tumor-bearing mice.
|
| Animal Model: | HBV-transgenic mice[3] | | Dosage: | 0-200 mg/kg | | Administration: | Vein injection, 5 days | | Result: | Reduced serum HBV DNA. |
| [IC 50]
Human Endogenous Metabolite; SIRT2: 2 μM (EC50); SIRT1: 50-180 μM (IC50) | [References]
[1] Francesca Scatozza, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020 Oct 7;39(1):211. DOI:10.1186/s13046-020-01719-3
[2] Hwang ES, et al. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci. 2017 Sep;74(18):3347-3362. DOI:10.1007/s00018-017-2527-8
[3] Li WY, et al. The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch Virol. 2016 Mar;161(3):621-30. DOI:10.1007/s00705-015-2712-8
[4] Zhang Y, et al. Nicotinamide promotes pancreatic differentiation through the dual inhibition of CK1 and ROCK kinases in human embryonic stem cells. Stem Cell Res Ther. 2021 Jun 25;12(1):362. DOI:10.1186/s13287-021-02426-2 |
|
| Company Name: |
Eastern Chemical Corp.
|
| Tel: |
631 273-0900 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList159/0_EN.htm |
|